Synonyms TC-5619
CAS Number 639489-84-2
PubChem (CID) 16727410
UNII UM3821998K YesY
Chemical and physical data
Formula C22H23N3O2
Molar mass 361.437 g/mol
3D model (Jmol) Interactive image

Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [1] Phase I clinical trials were completed successfully, and it was in phase II trials.[2]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[3] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[4] It was being studied for cognitive and memory enhancement.[5]

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[6] It was also discontinued for ADHD, and no longer seems to be being developed.[6]


This article is issued from Wikipedia - version of the 11/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.